Literature DB >> 22553292

Contrast-enhanced MR cholangiography: comparison of Gd-EOB-DTPA and Mn-DPDP in healthy volunteers.

K Bae1, J B Na, D S Choi, J M Cho, H C Choi, K-N Jeon, M J Park, H Y Choi, J E Kim, S H Chung.   

Abstract

OBJECTIVE: The purpose of this study was to compare the biliary enhancement dynamics of gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic-acid (Gd-EOB-DTPA) and mangafodipir trisodium (Mn-DPDP) for contrast-enhanced MR cholangiography (MRC) in healthy subjects.
METHODS: 15 healthy volunteers underwent MRI at 1.5 T with volumetric interpolated breath-hold examination sequence. Each volunteer was scanned once for each contrast agent. The signal-to-noise ratio (SNR) of the liver parenchyma and common hepatic duct (CHD) and the contrast-to-noise ratio (CNR) of CHD to liver parenchyma were evaluated and compared before and at several time points (5, 15, 30, 45, 60, 90, and 120 min) after injection of each agent.
RESULTS: SNR was significantly higher for Gd-EOB-DTPA than for Mn-DPDP in liver parenchyma after 5 min and in CHD after 15 min (p<0.05). CNR of CHD to liver parenchyma using Gd-EOB-DTPA showed an initial decrease at 5 min post-injection followed by a steep increase to a peak at 15 min post-injection. CNR using Mn-DPDP showed a steady increase to a peak at 15 min post-injection without an initial decrease. At 15 min, the value of CNR was significantly higher for Gd-EOB-DTPA than for Mn-DPDP (p<0.05).
CONCLUSION: For both contrast agents, CNR reached a peak at 15 min after contrast injection. At this time point, CNR of Gd-EOB-DTPA was significantly higher than that of Mn-DPDP. Therefore, Gd-EOB-DTPA may provide better contrast-enhanced MRC than Mn-DPDP at 15 min after contrast administration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22553292      PMCID: PMC3487056          DOI: 10.1259/bjr/22238911

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  25 in total

1.  Clinical significance of magnetic resonance cholangiopancreatography (MRCP) compared to endoscopic retrograde cholangiopancreatography (ERCP).

Authors:  R E Hintze; A Adler; W Veltzke; H Abou-Rebyeh; R Hammerstingl; T Vogl; R Felix
Journal:  Endoscopy       Date:  1997-03       Impact factor: 10.093

2.  The uptake of Mn-DPDP by hepatocytes is not mediated by the facilitated transport of pyridoxine.

Authors:  B Gallez; C Baudelet; J Adline; V Charbon; D M Lambert
Journal:  Magn Reson Imaging       Date:  1996       Impact factor: 2.546

3.  Optimal MR cholangiopancreatographic sequence and its clinical application.

Authors:  H Irie; H Honda; T Tajima; T Kuroiwa; K Yoshimitsu; K Makisumi; K Masuda
Journal:  Radiology       Date:  1998-02       Impact factor: 11.105

4.  Choledocholithiasis and bile duct stenosis: diagnostic accuracy of MR cholangiopancreatography.

Authors:  C D Becker; M Grossholz; M Becker; G Mentha; R de Peyer; F Terrier
Journal:  Radiology       Date:  1997-11       Impact factor: 11.105

5.  MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers.

Authors:  C Wang; P B Gordon; S O Hustvedt; D Grant; A T Sterud; I Martinsen; H Ahlström; A Hemmingsson
Journal:  Acta Radiol       Date:  1997-07       Impact factor: 1.701

6.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.

Authors:  B Hamm; T Staks; A Mühler; M Bollow; M Taupitz; T Frenzel; K J Wolf; H J Weinmann; L Lange
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

7.  Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system.

Authors:  G Schuhmann-Giampieri; H Schmitt-Willich; W R Press; C Negishi; H J Weinmann; U Speck
Journal:  Radiology       Date:  1992-04       Impact factor: 11.105

8.  Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans.

Authors:  G Schuhmann-Giampieri; M Mahler; G Röll; R Maibauer; S Schmitz
Journal:  J Clin Pharmacol       Date:  1997-07       Impact factor: 3.126

9.  Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.

Authors:  O Clément; A Mühler; V Vexler; Y Berthezène; R C Brasch
Journal:  Invest Radiol       Date:  1992-08       Impact factor: 6.016

Review 10.  Gadobenate dimeglumine (Gd-BOPTA). An overview.

Authors:  M A Kirchin; G P Pirovano; A Spinazzi
Journal:  Invest Radiol       Date:  1998-11       Impact factor: 6.016

View more
  2 in total

1.  Non-invasive detection of biliary leaks using Gd-EOB-DTPA-enhanced MR cholangiography: comparison with T2-weighted MR cholangiography.

Authors:  Mecit Kantarcı; Berhan Pirimoglu; Nevzat Karabulut; Ummugulsum Bayraktutan; Hayri Ogul; Gurkan Ozturk; Bulent Aydinli; Yesim Kizrak; Suat Eren; Sinan Yilmaz
Journal:  Eur Radiol       Date:  2013-05-22       Impact factor: 5.315

2.  Diagnosis of Cholecysto-Colonic Fistula Using Gadoxetic Acid - Magnetic Resonance Cholangiography.

Authors:  A B Mourri; M Lemort; Y M Bensouda; J L Engelholm
Journal:  J Belg Soc Radiol       Date:  2015-09-15       Impact factor: 1.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.